Microplastics — plastic particles under 5mm, and nanoplastics under 1μm — have been detected in virtually every human tissue studied since the analytical capabilities to detect them became available. A landmark 2022 study published in Environment International detected microplastics in 17 of 22 human blood samples at mean concentrations of 1.6 μg/mL. Subsequent studies have confirmed microplastic presence in lung tissue, placenta, breast milk, liver, kidney, testes, and in 2024, arterial plaques — where their presence was associated with higher rates of myocardial infarction and stroke. The healthcare industry, as a major user of plastic materials, has both a responsibility to understand this evidence and an opportunity to lead in reducing unnecessary plastic exposure.
The Emerging Health Evidence
The NEJM Evidence study published in March 2024 found that patients with carotid atherosclerotic plaques containing detectable microplastics and nanoplastics had a 4.5× higher risk of myocardial infarction, stroke, or death from any cause over 34 months compared to patients without detectable plaque plastics — after adjustment for traditional cardiovascular risk factors. This is the strongest direct human outcome evidence linking microplastic body burden to clinically meaningful harm. Mechanistic studies suggest: inflammatory cytokine activation (IL-6, TNF-α, NF-κB pathway) from microplastic-cell interactions; oxidative stress generation; and endocrine disruption from plasticizers (phthalates, bisphenols) that leach from plastic particles. The World Health Organization's 2023 microplastics and human health report concluded that current evidence warrants precautionary action despite ongoing uncertainty.
Healthcare Supply Implications
Healthcare facilities are major contributors to plastic waste — estimated at 25% of total plastic waste in some health system analyses — and are also environments where plastic-containing medical devices, IV tubing, and packaging are in direct contact with patients. PVC-free IV bags and tubing (eliminating DEHP plasticizer migration into IV solutions) have been available from B.Braun and Baxter for years and are standard in many European hospitals. BPA-free materials are now widespread across food-contact medical packaging. The evidence supporting more aggressive reduction of unnecessary plastic contact in clinical settings continues to grow. Our medical supply catalog includes products from manufacturers committed to plasticizer-free materials for patient contact applications — contact us at our procurement team for guidance on plastic-reduced product alternatives. Healthcare facilities can find relevant diagnostic equipment in our catalog.
